
An international pharma collaboration of AstraZeneca, GlaxoSmithKline, Columbia University and Harvard Medical School has identified a promising drug candidate for malaria that kills the parasite rapidly and over a long duration. The research funded by AstraZeneca India and MMV involved over 50 scientists globally with varying skill sets and expertise. The drug, kwon as triaminopyrimidine (TAP), is currently evaluated by Medicines for Malaria Venture ...

http://ift.tt/19MDS5c
http://ift.tt/1BWgEAm
No comments:
Post a Comment